ClinicalTrials.gg
RecruitingNCT06992089Updated Nov 12, 2026

SHort Of Pace - Heart Failure (SHOP-HF)

An interventional study of Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific) in Heart Failure With Preserved Ejection Fraction, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia — 5 open to participants now, 6 under way, 1 of them phase 3. Heart Failure · Fundación para la Investigación del Hospital Clínico de Valencia.

Planned enrollment
12th of 14
30 · median 64
Started
2025
the only one that year
No phase
7 of 14
4 open now
Registered
13th of 14
by date

Among the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 7 with no phase, and was the 13th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Fundación para la Investigación del Hospital Clínico de Valencia, or all of them as a file.
02

Study summary

This study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy Clinical research with CE-marked medical device . The crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. The population includes patients with the diagnosis of stable HFpEF according to criteria of the European Society of Cardiology and New York Heart Association (NYHA) functional class II-III/IV, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (CI).

All patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing On followed by pacing Off in two periods of 3 months; or (b) programming of the pacemaker with pacing Off followed by pacing On in two periods of 3 months. The study will be conducted in three centers in Spain. Discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable symptomatic heart failure ( functional class ≥II) during the last month.
  • Diagnosis criteria of HFpEF according to ESC guidelines:

    1. symptoms and signs of HF.
    2. ≥50% by Simpson method.
    3. proBNP >125 pg/mL in the last month.
    4. at least one additional criterion: 1. relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement); and/or 2. Diastolic dysfunction.
  • Left ventricular hypertrophy was defined as wall thickness > 10 mm.
  • Small ventricular volume was defined as indexed left ventricular end diastolic volume \< 45 ml/m2.
  • Adults ≥18 years old.
  • Previous admission for acute heart failure.
  • Chronotropic incompetence assessed by CPET, defined as: [(HRmax - HRrest)]/[(220 - age) - (HRrest)] \< 0.62.
  • Resting heart rate \< 65 bpm in sinus rhythm or 70 bmp in atrial fibrillation.

Exclusion criteria

Exclusion Criteria:

  • Inability to perform a valid baseline exercise test.
  • Significant primary pulmonary disease; including pulmonary arterial hypertension, chronic thromboembolic pulmonary disease or .
  • Patient with prior history of \<50%.
  • History of an acute coronary syndrome in the previous 12 months.
  • Effort angina or signs of ischemia during CPET.
  • RER threshold at \<1.05 at the CPET.
  • Significant primary moderate to severe valvular disease.
  • Any other comorbidity with a lower than 1 year.
  • Heart rate at rest > 75 lpm.
  • Other pacemaker indication.
  • Pregnant women.
  • Baseline rhythm different from sinus rhythm or atrial fibrillation.
  • Active treatment with beta-blockers, digitalis or non dihidropiridine calcium channel blockers.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pacing on

    Pacemaker stimulation programmed as AAIR / DDDR / VVIR with the basic stimulation frequency and the rate response as follows (pacing on): * Basic heart rate: derived from the averaged resting heart rates of healthy adults according to height and LVEF. * Rate response through a combination of minute ventilation and accelerometer, with an accelerometer response factor between 3 and 8 and an activity threshold ranging from medium-low to medium. Within these ranges, settings will be individualised by the investigator according to the participant's chronotropic response, activity profile and clinical tolerance. Each adjustment will be documented in the source records and case report form. These programming criteria will also apply when pacing-on is initiated at crossover.

    Device: Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)

  • Placebo comparator
    Pacing off

    VVI 30 bpm

    Device: Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)

Interventions

  • DeviceDual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)

    Dual-chamber cardiac pacemaker (Proponent MRI L211, Proponent MRI L231, Accolade MRI L311 or Accolade MRI L331, Boston Scientific), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™+ MRI pacing lead) and right ventricular lead (INGEVITY™+ MRI pacing lead). Single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific), with rate-adaptive pacing of the ventricles. There will be an associated right ventricular lead (INGEVITY™+ MRI pacing lead).

06

What researchers measure

Primary outcomes

  1. Peak oxygen uptake

    The primary endpoint of the study is absolute and relative changes in peak oxygen uptake (peakVO2) after three months of pacemaker stimulation.

    Time frame: 3 months after the pacemarker stimulation

Secondary outcomes

  1. Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Absolute changes in quality of live assessed by Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Time frame: From randomization until the end of study in month 7

  2. E/E' ratio

    Absolute changes in echocardiogram parameters (E/E' ratio)

    Time frame: From baseline until the end of study in month 7

  3. Left ventricular volume index

    Absolute changes in echocardiogram parameters (Left ventricular volume index)

    Time frame: From baseline until the end of study in month 7

  4. Left atrial volume index

    Absolute changes in echocardiogram parameters (Left atrial volume index)

    Time frame: From baseline until the end of study in month 7

  5. Pro-B-type natriuretic peptide

    Absolute and relative changes in prognostic biomarkers (pro-B-type natriuretic peptide)

    Time frame: From baseline until the end of study in month 7

  6. Serum carbohydrate antigen 125

    Absolute and relative changes in prognostic biomarkers (serum carbohydrate antigen 125).

    Time frame: From baseline until the end of study in month 7

Other outcomes

  1. Acute HF hospitalizations

    Total number of episodes of acute HF hospitalizations.

    Time frame: From baseline until the end of study in month 7

  2. Worsening HF not requiring hospitalization

    Total episodes of worsening HF not requiring hospitalization

    Time frame: From baseline until the end of study in month 7

  3. Mortality

    Mortality

    Time frame: From baseline until the end of study in month 7

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 28, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2027was Jun 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Nov 12, 2026
Study completion
Jun 2026→Jun 2027
Nov 12, 2026
Interventions
Changed Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®)→Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Jun 2026→Jun 2027
    Interventions Changed Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®)→Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06992089
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Jun 17, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Julio Núñez, Doctor
Contact
yulnunez@gmail.es
652856689
Vicente Bertomeu, Doctor
Contact
vbertog@gmail.com
Julio Núñez, Doctor
principal investigator · Hospital Clínico Universitario de Valencia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion